Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Hematology

The Long-Term View: Surveillance and Survivorship in SDS

At a Glance

Children with Shwachman-Diamond syndrome need lifelong, coordinated follow-up even after a bone marrow transplant. Regular blood and marrow checks, along with monitoring of growth, bones, liver, immunity, learning, emotional health, and transplant effects, can identify problems early.

Managing Shwachman-Diamond Syndrome (SDS) is often described as a marathon rather than a sprint. Because SDS is a multisystem condition, staying ahead of potential complications requires a structured, lifelong commitment to medical surveillance [1]. While the schedule can feel demanding, the goal is proactive care—identifying changes early when they are most manageable, rather than waiting for symptoms to appear [2].

Hematologic Surveillance

A critical piece of SDS monitoring is bone marrow evaluation. While intervals are individualized (some stable patients may wait 1-3 years between exams), it detects “silent” changes that blood counts miss [3].

When performed, an evaluation should generally include:

  • Morphology: A specialist (pathologist) looks at the shape and size of the cells to check for dysplasia (abnormal growth) [4].
  • Cytogenetics: Mapping the chromosomes to look for “clones” like i(7)(q10) or del(20q) [5].
  • Molecular/NGS Testing: Searching for specific somatic mutations, such as TP53, which can signal an increased risk of leukemia [6][7]. (This is increasingly used, though not always universally required at every single check).

In between these biopsies, your child will have regular Complete Blood Counts (CBCs)—typically every 3 to 6 months (or more frequently based on specific risks) [2][1].

Monitoring the Whole Body

Beyond the bone marrow, a multidisciplinary team must track how SDS affects other organs. This “survivorship” care continues even if a child has had a bone marrow transplant, as the genetic mutation remains in the rest of the body [8].

System What is Monitored Why it Matters
Growth & Endocrine Height, weight (using SDS charts), and bone age [9][10]. Delayed bone age and short stature are common. (Note: True growth hormone deficiency is a separate issue that can affect some patients) [9].
Bone Health Bone Mineral Density (BMD) via DXA scans [9]. Osteopenia (low bone density) occurs in a subset of patients, but pediatric DXA results must be height- and age-adjusted [9].
Liver Liver enzymes (ALT/AST) and sometimes ultrasound or elastography [11][12]. Transient elevated liver enzymes or hepatomegaly are common in childhood; a smaller subset develops scarring (fibrosis) [11].
Neurocognitive Neuropsychological testing for executive function and learning [13]. Weaknesses in mathematics, spelling, and motor integration are seen in some children and may require specialized school support [13].
Immune System Immunoglobulin levels and B-cell subsets [14]. Low antibodies can increase infection risk even if white blood cell counts look okay [14].

Navigating “Scanxiety” and Emotional Health

For many families, the time surrounding surveillance is marked by scanxiety—the intense anxiety that builds before medical tests and while waiting for results [15]. This emotional burden is a recognized part of living with a rare condition [16].

  • Validation: It is normal to feel hyper-vigilant or stressed as the “anniversary” of a biopsy approaches [17].
  • Communication: Talk to your team about how results will be shared. Knowing exactly when and from whom you will hear can help reduce the “limbo” period [2].
  • Support: Incorporating child life specialists for the child and mental health support for caregivers is not an “extra”—it is a core part of a sustainable surveillance plan [18][19].

Life After Transplant and Transition to Adulthood

If your child undergoes a bone marrow transplant (HSCT), surveillance follows a completely separate transplant protocol. While the risk of leukemia is greatly reduced, the risk for non-blood complications (like pancreatic insufficiency or liver issues) remains [8]. Additionally, long-term follow-up is needed to monitor for transplant-related effects on growth, fertility, and secondary cancers [20][21].

As your child grows, connecting with genetic counselors and adult hematology specialists will ensure they smoothly transition from pediatric care into informed adult self-management.

Common questions in this guide

How often does a child with SDS need blood counts and bone marrow checks?
The schedule is individualized. CBCs are often done every 3 to 6 months, while stable children may have a bone marrow evaluation about every 1 to 3 years; the SDS team may recommend more frequent testing when risks or results change.
What can a bone marrow evaluation detect in SDS?
It can assess how blood cells look, check chromosomes for changes, and use molecular testing to look for mutations such as TP53. These findings may reveal changes before routine blood counts do and can help identify increased leukemia risk.
What health checks are important beyond blood tests?
Follow-up may include growth and bone-age checks, endocrine review, height- and age-adjusted DXA bone-density scans, liver blood tests and sometimes imaging, immune testing, and neuropsychological assessment. These checks look for changes in growth, bones, liver, infection protection, learning, and motor skills.
Does a bone marrow transplant end the need for SDS follow-up?
No. A transplant can greatly reduce leukemia risk, but the underlying genetic change remains in the rest of the body, so ongoing monitoring for pancreatic, liver, growth, fertility, and secondary-cancer concerns is still needed.
How can families cope with anxiety before biopsies and results?
Pre-test anxiety is common in families living with a rare condition. Agreeing in advance on when and how results will be shared, and using child-life specialists for the child plus mental-health support for caregivers, can make surveillance more manageable.
How should SDS care transition to adulthood?
A planned transition can connect the young person with genetic counselors and adult hematology specialists before pediatric care ends. The goal is coordinated follow-up and a growing ability to understand appointments, results, and self-management.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Shwachman-Diamond syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How frequently should we be doing CBCs in between our bone marrow biopsies?
  2. 2.Is my child's latest bone marrow sample being sent for both cytogenetics and molecular (NGS) testing to look for TP53 mutations?
  3. 3.Based on my child's current height velocity, should we be scheduling an evaluation with a pediatric endocrinologist this year?
  4. 4.When was my child's last bone density (DXA) scan, and has it been interpreted adjusted for height?
  5. 5.Are we monitoring my child's liver with ultrasound or elastography in addition to routine blood work?
  6. 6.Can we schedule a neuropsychological evaluation to establish a baseline for my child's school and learning needs?

References

References (21)
  1. 1

    Stem Cell Transplantation in Patients Affected by Shwachman-Diamond Syndrome: Expert Consensus and Recommendations From the EBMT Severe Aplastic Anaemia Working Party.

    Cesaro S, Donadieu J, Cipolli M, et al.

    Transplantation and cellular therapy 2022; (28(10)):637-649 doi:10.1016/j.jtct.2022.07.010.

    PMID: 35870777
  2. 2

    Monitoring and treatment of MDS in genetically susceptible persons.

    Davies SM

    Hematology. American Society of Hematology. Education Program 2019; (2019(1)):105-109 doi:10.1182/hematology.2019000020.

    PMID: 31808891
  3. 3

    Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study.

    Myers KC, Furutani E, Weller E, et al.

    The Lancet. Haematology 2020; (7(3)):e238-e246 doi:10.1016/S2352-3026(19)30206-6.

    PMID: 31879230
  4. 4

    Inherited bone marrow failure syndromes and germline predisposition to myeloid neoplasia: A practical approach for the pathologist.

    Li J, Bledsoe JR

    Seminars in diagnostic pathology 2023; (40(6)):429-442 doi:10.1053/j.semdp.2023.06.006.

    PMID: 37507252
  5. 5

    The frequent and clinically benign anomalies of chromosomes 7 and 20 in Shwachman-diamond syndrome may be subject to further clonal variations.

    Khan AW, Kennedy A, Furutani E, et al.

    Molecular cytogenetics 2021; (14(1)):54 doi:10.1186/s13039-021-00575-w.

    PMID: 34819134
  6. 6

    Predisposition to myeloid malignancies in Shwachman-Diamond syndrome: biological insights and clinical advances.

    Reilly CR, Shimamura A

    Blood 2023; (141(13)):1513-1523 doi:10.1182/blood.2022017739.

    PMID: 36542827
  7. 7

    Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.

    Kennedy AL, Myers KC, Bowman J, et al.

    Nature communications 2021; (12(1)):1334 doi:10.1038/s41467-021-21588-4.

    PMID: 33637765
  8. 8

    Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?

    Hudda Z, Myers KC

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):141-148 doi:10.1182/hematology.2023000471.

    PMID: 38066882
  9. 9

    Endocrine dysfunction in children with Shwachman-Diamond syndrome.

    Bogusz-Wójcik A, Kołodziejczyk H, Moszczyńska E, et al.

    Endokrynologia Polska 2021; (72(3)):211-216 doi:10.5603/EP.a2021.0014.

    PMID: 33619711
  10. 10

    Normative growth charts for Shwachman-Diamond syndrome from Italian cohort of 0-8 years old.

    Cipolli M, Tridello G, Micheletto A, et al.

    BMJ open 2019; (9(1)):e022617 doi:10.1136/bmjopen-2018-022617.

    PMID: 30782681
  11. 11

    Liver disease in Shwachman-Diamond syndrome: A comprehensive characterization across the age spectrum.

    Koo J, Schwarz D, Haney M, et al.

    Journal of pediatric gastroenterology and nutrition 2026; (82(6)):1357-1365 doi:10.1002/jpn3.70430.

    PMID: 41913528
  12. 12

    Liver stiffness in patients with Shwachman-Diamond syndrome.

    Sabharwal S, Grover A, Mitchell P, et al.

    JPGN reports 2026; (7(2)):200-206 doi:10.1002/jpr3.70138.

    PMID: 42110137
  13. 13

    Neuropsychological and Educational Outcomes in Shwachman-Diamond Syndrome-A Report From the North American Shwachman-Diamond Syndrome Registry.

    Koo J, Gerstle M, Cheng L, et al.

    Pediatric blood & cancer 2026; (73(11)):e70650 doi:10.1002/1545-5017.70650.

    PMID: 42657666
  14. 14

    Beyond neutropenia: Immunological evaluation of patients with Shwachman-Diamond syndrome.

    Gloude NJ, Brundige K, Loveless S, et al.

    British journal of haematology 2026; (209(1)):180-188 doi:10.1111/bjh.70553.

    PMID: 42185746
  15. 15

    Being the Pillar for Children with Rare Diseases-A Systematic Review on Parental Quality of Life.

    Boettcher J, Boettcher M, Wiegand-Grefe S, Zapf H

    International journal of environmental research and public health 2021; (18(9)) doi:10.3390/ijerph18094993.

    PMID: 34066738
  16. 16

    A "rotating menu" of medical uncertainty for families affected by telomere biology disorders: A qualitative interview study.

    Pearce E, Majid A, Brown T, et al.

    SSM. Qualitative research in health 2024; (6()) doi:10.1016/j.ssmqr.2024.100486.

    PMID: 39554689
  17. 17

    "I don't grieve as much as I used to": A qualitative study on parents of children with rare and undiagnosed conditions navigating grief in the context of uncertainty.

    Hoffmann TM, Friedrich B, Lewis C

    Journal of genetic counseling 2025; (34(6)):e70149 doi:10.1002/jgc4.70149.

    PMID: 41317142
  18. 18

    A web-based psychological support program for caregivers of children with rare chronic diseases: a randomized controlled trial.

    Tutus D, Niemitz M, Plener PL, et al.

    Orphanet journal of rare diseases 2024; (19(1)):27 doi:10.1186/s13023-024-03029-9.

    PMID: 38281056
  19. 19

    Development of the parental needs scale for rare diseases: a tool for measuring the supportive care needs of parents caring for a child with a rare disease.

    Pelentsov LJ, Fielder AL, Laws TA, Esterman AJ

    Journal of multidisciplinary healthcare 2016; (9()):425-33 doi:10.2147/JMDH.S113898.

    PMID: 27672327
  20. 20

    Growth Patterns in Shwachman-Diamond Syndrome: Findings from the North American Shwachman-Diamond Syndrome Registry.

    Schwarz L, Cheng L, Steltz S, et al.

    The Journal of pediatrics 2025; (287()):114780 doi:10.1016/j.jpeds.2025.114780.

    PMID: 40818805
  21. 21

    Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes.

    Bezzerri V, Api M, Allegri M, et al.

    International journal of molecular sciences 2020; (21(13)) doi:10.3390/ijms21134672.

    PMID: 32630050

This page explains long-term surveillance and survivorship in Shwachman-Diamond syndrome for informational purposes only and does not constitute medical advice. Your child’s SDS team should set the testing schedule and interpret results.